New here and will tell my story to date.
Was in a trial in 2010 at the very beginning of DAA trials.
Am a GT 1a and did trial of
Daclatasvir/peg/riba. As we have come to learn 8 yrs. later this was sup-optimal and I relapsed.
Unfortunately, ended up with quite a nasty Ns5a linked resistant mutation of H58d/Q30r
I am being tx. By Doc Feld(whom I have seen mentioned here) from CCO articles.
We waited until now for triple(vosevi) because of said resistance profile.
I am treating aggressively for 16 Wks(instead of the 12) and he added Riba from get go.
I am at week 7. VL at wk. 4 was Llod 15 and will test again at Wk 8.
After 41 yrs. infected fortunately still f2, however really want to get rid of this
Just posted this in case anyone else on vosevi or mav and wanted to weigh in.
Will keep updating
Diagnosed: 2001 GT1a , HCV since mid-70's.
Biopsy 2010 F1
Fibroscan and Fibrosure 2018 F2
Treated in trial 2010 with Dac/Peg/ Riba and Relapsed.
Resistance test 2017. Have Ns5a Rav Q30r/H58d enhanced from doing Dac.
Start Tx. Jan 18th/18 w/ Vosevi /Riba 12wks. plus 6 wks.Viekira Pak +Sof/Riba(From Dr Freeman @GP2U)
VL start: 1.6mill.ALT 125 AST 88
Wk. 4 Det @LLOQ <15.
VL Wk.8 UND Alt &Ast 22
Wk. 12 UND
EOT+12 >>>UND (SVR12)! ALT11 AST13
Nov6/18 SVR 24!